Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PYXS Stock Summary
Top 10 Correlated ETFs
PYXS
In the News
3 Biotech Stocks to Buy on the Dip: March 2024
One of the best dip-buying opportunities in biotech stocks to buy was in Viking Therapeutics (NASDAQ: VKTX ). After hitting a high of $99.41, VKTX dipped back to about $60.30.
All You Need to Know About Pyxis Oncology (PYXS) Rating Upgrade to Buy
Pyxis Oncology (PYXS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
Given the current risk-on sentiment, it is perhaps an ideal time for investors to scoop up some of the top biotech stocks. The stock market is booming, and with investors looking to take on more risk, a potential surge in biotech stocks seems likely.
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Wednesday, March 13, 2024 at 8:40 AM EST at the Leerink Partners Global Biopharma Conference, Miami Beach, Florida, where members of management will also host investor one-on-one meetings.
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
PYX-201, an EDB+FN-specific tumor stroma-targeting ADC, demonstrates potent anti-tumor efficacy across multiple human cancers in PDX tumor models
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
With new innovation, high demand for better treatment, pharmaceutical companies strengthening pipelines and a resurgence of mergers and acquisitions, biotech stocks could offer some of the most explosive opportunities of the year. “What's more, big pharmaceutical companies with sizable piles of cash and the need to address patent expirations on some top-selling products later this decade will be hunting for companies with innovative drugs in development,” says Morningstar.com.
Down -15.56% in 4 Weeks, Here's Why You Should You Buy the Dip in Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc. (PYXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference
BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will present a company overview at the BTIG Virtual Biotechnology Conference on August 7, 2023 at 3:00 PM EST. The Pyxis Oncology management team will also host investor meetings that same day. To join the conference, email info@btig.com.
Pyxis Oncology, Inc. (PYXS) Upgraded to Strong Buy: What Does It Mean for the Stock?
Pyxis Oncology, Inc. (PYXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pyxis Oncology: A High-Stakes Gambit In The Battle Against Solid Tumors
Pyxis Oncology is developing next-generation therapeutics, including antibody-drug conjugates and immuno-oncology programs, to target solid tumors resistant to current treatments. PYXS's lead product candidates, PYX-201 and PYX-106, are currently in Phase 1 clinical trials, with promising preclinical results and unique targeting mechanisms. Pyxis Oncology presents a 'Buy' opportunity for high-risk-tolerant investors, but investors should monitor the progress of ongoing Phase 1 trials and the competitive landscape.
PYXS Financial details
PYXS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.12 | -0.58 | -9.6 | -3.57 | -1.85 | |
Operating cash flow per share | -0.1 | -0.46 | -4.16 | -2.7 | -1.77 | |
Free cash flow per share | -0.1 | -0.52 | -4.22 | -2.9 | -1.94 | |
Cash per share | 0.9 | 0.37 | 32.35 | 5.43 | 3.03 | |
Book value per share | -0.13 | -0.71 | 30.77 | 4.87 | 3.15 | |
Tangible book value per share | -0.13 | -0.71 | 30.77 | 4.87 | 2.6 | |
Share holders equity per share | -0.13 | -0.71 | 30.77 | 4.87 | 3.15 | |
Interest debt per share | 0 | 0.04 | 0.02 | 0.49 | 0.53 | |
Market cap | 290.07M | 292.07M | 93.17M | 44.26M | 71.83M | |
Enterprise value | 270.4M | 284.77M | -181.4M | -116.11M | 82.02M | |
P/E ratio | -108.85 | -22.89 | -1.14 | -0.38 | -0.97 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -129.56 | -28.96 | -2.64 | -0.5 | -1.02 | |
PFCF ratio | -129.56 | -25.25 | -2.6 | -0.46 | -0.93 | |
P/B Ratio | -100.93 | -18.67 | 0.36 | 0.28 | 0.57 | |
PTB ratio | -100.93 | -18.67 | 0.36 | 0.28 | 0.57 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -93.92 | -22.92 | 2.86 | 0.94 | -1 | |
EV to operating cash flow | -120.77 | -28.24 | 5.13 | 1.3 | -1.16 | |
EV to free cash flow | -120.77 | -24.62 | 5.06 | 1.21 | -1.06 | |
Earnings yield | -0.01 | -0.04 | -0.88 | -2.66 | -1.03 | |
Free cash flow yield | -0.01 | -0.04 | -0.38 | -2.16 | -1.08 | |
Debt to equity | -0.01 | -0.05 | 0 | 0.12 | 0.17 | |
Debt to assets | 0 | 0.08 | 0 | 0.09 | 0.12 | |
Net debt to EBITDA | 6.83 | 0.59 | 4.32 | 1.3 | -0.12 | |
Current ratio | 26.88 | 2.2 | 14.9 | 5.9 | 4.84 | |
Interest coverage | 0 | 0 | 0 | 44.67 | 0 | |
Income quality | 0.81 | 0.79 | 0.46 | 0.74 | 0.96 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0.14 | |
Capex to operating cash flow | 0 | 0.15 | 0.02 | 0.07 | 0.1 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -3.16 | -0.83 | -9.03 | -3.49 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.6 | 3.03 | 81.52 | 19.78 | 11.45 | |
ROIC | 0.97 | 0.91 | -0.29 | -0.61 | -0.49 | |
Return on tangible assets | -0.13 | -1.26 | -0.29 | -0.56 | -0.49 | |
Graham Net | -0.14 | -0.8 | 30.14 | 3.92 | 1.88 | |
Working capital | 18.97M | 4.41M | 259.97M | 154.98M | 98.85M | |
Tangible asset value | -2.87M | -15.65M | 261.31M | 160.82M | 103.56M | |
Net current asset value | -2.98M | -17.69M | 259.97M | 136.06M | 78.75M | |
Invested capital | -0.01 | -0.05 | 0 | 0.12 | 0.17 | |
Average receivables | 0 | 0 | 0 | 299K | 299K | |
Average payables | 0 | 784K | 6.51M | 9.52M | 5.5M | |
Average inventory | 0 | 0 | 0 | 437K | 437K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 885.37 | 3.49K | 1.41K | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 173.75 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0.41 | 0.1 | 0.26 | 0 | |
Inventory turnover | 0 | 0 | 0 | 2.1 | 0 | |
ROE | 0.93 | 0.82 | -0.31 | -0.73 | -0.59 | |
Capex per share | 0 | -0.07 | -0.06 | -0.19 | -0.17 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0.69 | -0.5 | -0.41 | -0.56 | -0.27 | |
Operating cash flow per share | -0.53 | -0.76 | -0.29 | -0.43 | 0 | |
Free cash flow per share | -0.58 | -0.88 | -0.35 | -0.43 | 0 | |
Cash per share | 5.43 | 4.22 | 3.72 | 3.22 | 2.08 | |
Book value per share | 4.87 | 4.3 | 3.78 | 3.34 | 2.16 | |
Tangible book value per share | 4.87 | 4.3 | 3.78 | 2.8 | 2.2 | |
Share holders equity per share | 4.87 | 4.3 | 3.78 | 3.34 | 2.16 | |
Interest debt per share | -1.21 | 0.52 | 0.55 | 0.52 | 0.02 | |
Market cap | 44.26M | 141.76M | 98.28M | 82.25M | 104.64M | |
Enterprise value | -116.11M | 108.95M | 93.64M | 89.15M | 114.84M | |
P/E ratio | 0.48 | -2.02 | -1.55 | -0.89 | -1.68 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -2.55 | -5.28 | -8.91 | -4.68 | 0 | |
PFCF ratio | -2.3 | -4.54 | -7.39 | -4.66 | 0 | |
P/B Ratio | 0.28 | 0.93 | 0.68 | 0.6 | 0.83 | |
PTB ratio | 0.28 | 0.93 | 0.68 | 0.6 | 0.83 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 3.07 | -5.25 | -5.32 | -3.52 | -6.46 | |
EV to operating cash flow | 6.68 | -4.06 | -8.49 | -5.07 | 0 | |
EV to free cash flow | 6.03 | -3.49 | -7.05 | -5.05 | 0 | |
Earnings yield | 0.52 | -0.12 | -0.16 | -0.28 | -0.15 | |
Free cash flow yield | -0.43 | -0.22 | -0.14 | -0.21 | 0 | |
Debt to equity | 0.12 | 0.13 | 0.15 | 0.16 | 0.01 | |
Debt to assets | 0.09 | 0.11 | 0.12 | 0.12 | 0.01 | |
Net debt to EBITDA | 4.24 | 1.58 | 0.26 | -0.27 | -0.57 | |
Current ratio | 5.9 | 13.46 | 16.18 | 4.91 | 4.84 | |
Interest coverage | 0.64 | 12.25 | 0 | 0 | 0 | |
Income quality | 0.48 | 1.39 | 0.69 | 0.76 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0.12 | 0 | |
Capex to operating cash flow | 0.11 | 0.16 | 0.2 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -9.68 | -23.19 | -4.31 | -0.12 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 8.71 | 6.93 | 5.94 | 6.47 | 3.61 | |
ROIC | 0.12 | -0.1 | -0.09 | -0.14 | -0.12 | |
Return on tangible assets | 0.11 | -0.1 | -0.09 | -0.14 | -0.09 | |
Graham Net | 4.01 | 3.36 | 2.94 | 2.04 | 1.29 | |
Working capital | 154.98M | 144.58M | 140.08M | 110.76M | 98.85M | |
Tangible asset value | 160.82M | 152.16M | 145.28M | 115.65M | 127.87M | |
Net current asset value | 136.06M | 125.54M | 119.35M | 90.35M | 78.75M | |
Invested capital | 0.12 | 0.13 | 0.15 | 0.16 | 0.01 | |
Average receivables | 299K | 299K | 0 | 0 | 0 | |
Average payables | 6.3M | 5.56M | 2.67M | 2.31M | 3.6M | |
Average inventory | 3.17M | 3.17M | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 1.38K | 1.08K | 168.03 | 440.03 | 0 | |
Days of inventory on hand | 1.23K | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.07 | 0.08 | 0.54 | 0.2 | 0 | |
Inventory turnover | 0.07 | 0 | 0 | 0 | 0 | |
ROE | 0.14 | -0.12 | -0.11 | -0.17 | -0.12 | |
Capex per share | -0.06 | -0.12 | -0.06 | 0 | 0 |
PYXS Frequently Asked Questions
What is Pyxis Oncology, Inc. stock symbol ?
Pyxis Oncology, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol PYXS
What is Pyxis Oncology, Inc. stock quote today ?
Pyxis Oncology, Inc. stock price is $4.26 today.
Is Pyxis Oncology, Inc. stock public?
Yes, Pyxis Oncology, Inc. is a publicly traded company.